Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

stada arzneimittel ag - adalimumab - arthritis, rheumatoid; arthritis, juvenile rheumatoid; spondylitis, ankylosing; arthritis, psoriatic; psoriasis; hidradenitis suppurativa; crohn disease; colitis, ulcerative; uveitis - immunsuppressiva - rheumatoid arthritislibmyris in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (dmards) including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. libmyris can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumab har visat sig minska risken för progression av ledskador mätt med röntgen och förbättra den fysiska funktionen, när det ges i kombination med metotrexat. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritislibmyris in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more dmard. libmyris can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab har inte studerats hos patienter yngre än 2 år. enthesitis-related arthritislibmyris is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritisankylosing spondylitis (as)libmyris is indicated for the treatment of adults with severe active as who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of aslibmyris is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). psoriatic arthritislibmyris is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous dmard therapy has been inadequate. adalimumab har visat sig minska risken för progression av perifer ledskada mätt med röntgen hos patienter med polyartikulär symmetrisk subtyper av sjukdomen och för att förbättra fysisk funktion. psoriasislibmyris is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasislibmyris is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)libmyris is indicated for the treatment of active moderate to severe hs (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 och 5. crohn’s diseaselibmyris is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseaselibmyris is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitislibmyris is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitislibmyris is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitislibmyris is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitislibmyris is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

medartuum ab - ibuprofen - depottablett - 800 mg - sojalecitin hjälpämne; ibuprofen 800 mg aktiv substans - ibuprofen

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

2care4 aps - ibuprofen - depottablett - 800 mg - ibuprofen 800 mg aktiv substans - ibuprofen

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - karboplatin - koncentrat till infusionsvätska, lösning - 10 mg/ml - karboplatin 10 mg aktiv substans - karboplatin

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

pfizer ab - vorikonazol - filmdragerad tablett - 200 mg - vorikonazol 200 mg aktiv substans; laktosmonohydrat hjälpämne - vorikonazol

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

pfizer ab - vorikonazol - pulver till infusionsvätska, lösning - 200 mg - vorikonazol 1 mg aktiv substans; sulfobutylbetadexnatrium hjälpämne - vorikonazol

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

pfizer ab - vorikonazol - pulver till oral suspension - 40 mg/ml - sackaros hjälpämne; vorikonazol 40 mg aktiv substans; natriumbensoat hjälpämne - vorikonazol

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

pfizer ab - vorikonazol - filmdragerad tablett - 50 mg - vorikonazol 50 mg aktiv substans; laktosmonohydrat hjälpämne - vorikonazol

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

orifarm ab - zolmitriptan - nässpray, lösning - 5 mg/dos - zolmitriptan 5 mg aktiv substans - zolmitriptan

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

orifarm ab - zolmitriptan - nässpray, lösning - 5 mg/dos - zolmitriptan 5 mg aktiv substans - zolmitriptan